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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 

















• Here genomic 
epidemiology was 
used to investigate 
the introduction and 
spread of SARS-
CoV-2 in the Boston 
area across the first 
wave of the 
pandemic from 
March to May 2020 
• Results evidence 
the importance of 
superspreading 
events in shaping 
the course of the 
pandemic and 
illustrate how some 
introductions in an 
urban setting can 
lead to a 
disproportionate 
















up to 8 months 





memory (B cells, 
antibodies, memory 
CD4+ T cells, 
and/or CD8+ T 
cells) is the basis 
for durable 
protective immunity 
after infections or 







memory would help 
assess the likely 
future course of the 
COVID-19 
pandemic 
• This study involved 
254 samples from 
188 COVID-19 
cases across the 
range of severity of 
COVID-19, 
including 43 
samples at 6 to 8 
months after 
infection 
• Authors found a 
high degree of 




persisted into the 
immune memory 
phase to the virus 
• However, immune 





greater that 90% of 
subjects for more 
than 5 months after 
infection 
• Circulating antibody 
titres were not 








do not reflect the 
richness and 
durability of immune 
memory to SARS-
CoV-2 
• Despite this 
heterogeneity of 
immune responses, 




19 disease is a 
possibility for most 
individuals 



















• China successfully 
controlled its initial 
COVID-19 epidemic in 
March 2020 and has 
since focused on 
preventing importation 
of SARS-CoV-2 
• This retrospective 
study assessed the 
proportion of 
international entrants 
to China with 
asymptomatic SARS-
CoV-2 infection (as 
determined by PCR 
test result) from 16 
April to 12 October 
2020  
• Findings were that a 
high and increasing 
proportion of 
asymptomatic 
infections among all 
SARS-CoV-2-positive 
international entrants 











Summary             Keywords 
05.02.2021 Peginterferon 













• No approved therapy 




investigating the safety 
and efficacy of 
subcutaneous injection 
with peginterferon 
lambda, a type III 
interferon involved in 
innate antiviral 
responses with activity 
against respiratory 




• Peginterferon lambda 
was safe and well 
tolerated 
• Peginterferon lambda 
accelerated viral 
decline in outpatients 
with COVID-19, 
increasing the 
proportion of patients 
with viral clearance by 
day 7, especially in 
those with high 
baseline viral load 
• Treatment with 
peginterferon lambda 
early in the course of 
disease has the 
potential to prevent 
clinical deterioration 
and shorten duration of 
viral shedding – 
important in reducing 
transmission and 












The Lancet | 
Article 
• Evaluation of the safety 
and efficacy of 
azithromycin, on the 










actions, in patients 
admitted to hospital 
with COVID-19 
• Azithromycin did not 
improve survival or 
other prespecified 
clinical outcomes in 
patients admitted to 
hospital with COVID-19 
• Azithromycin should 
not be used to treat 
patients admitted to 
hospital with COVID-19 




















Medicine | Brief 
Communication 
• Here the Pfizer-
BioNTech COVID-19 
vaccine is shown to 
neutralize SARS-CoV-2 
with the N501Y and 
E484K mutations, which 
are present in strains 
from the UK and South 
Africa, in blood plasma 
from 20 people who 
recently had two shots of 
the Pfizer-BioNTech 
vaccine 
• Surveillance of the 
ongoing evolution of 
SARS-CoV-2 should 
work with preparations 
for the possibility that 
future mutations might 




















print (not peer 
reviewed) 
• Oxford’s ChAdOx1 
vaccine has similar 
efficacy against the 
B.1.1.7 ‘Kent’ 
coronavirus strain to 
previously circulating 
variants 
• The ChAdOx1 vaccine 
also results in a 







of shedding and viral 
load, which may result in 
reduced transmission 
02.02.2021 Safety and 









analysis of a 
randomised 
controlled 
phase 3 trial 
in Russia 
The Lancet | 
Article 




(Sputnik V), showed a 
good safety profile and 
induced strong humoral 
and cellular immune 
responses in participants 
in phase 1/2 clinical trials 
• Here results of the 
randomised, double-
blind, placebo-controlled, 
phase 3 trial in Moscow, 
Russia, including 21, 862 
participants, are reported 
• Interim analysis of the 
phase 3 trial of Gam-
COVID-Vac showed 
91.6% efficacy against 
COVID-19 and was well 
tolerated in a large 
cohort 
• The vaccine is stored 
and distributed at -18oC 
but storage at 2-8oC has 
also been approved by 
the Ministry of Health of 

























HIV | Article 
• This study aimed to 
measure the impact of the 
2020 national COVID-19 
lockdown on HIV testing 
and treatment in KwaZulu-
Natal, South Africa where 
1.7 million people are living 
with HIV 
• A large dataset from urban 
and rural primary care 
clinics between 1 Jan 2018 
and 31 July 2020 was 
analysed with use of 





analysis to account for 
longer-term trends 
• ART provision was 
generally maintained during 
the 2020 COVID-19 
lockdown, but HIV testing 
and ART initiations were 
heavily impacted 
• Authors recommend that 
strategies to increase and 
catch up with HIV testing 
and treatment initiation 
should be implemented, 
alongside ongoing efforts to 
maintain treatment provision 
Comments, Editorials, Opinions, Blogs, News  
Publication 
date 
Title/URL Journal | Article type 
08.02.2021 Covid-19: First UK vaccine safety data are 
“reassuring,” says regulator 
BMJ | News 
07.02.2021 ChAdOx1 nCov-19 provides minimal protection 
against mild-moderate COVID-19 infection from 
B.1.351 coronavirus variant in young South African 
adults 
University of Oxford | 
News 
06.02.2021 Understanding variants of SARS-CoV-2 The Lancet | World 
Report 
06.02.2021 WHO team begins COVID-19 origin investigation The Lancet | World 
Report 
06.02.2021 Genomic sequencing in pandemics The Lancet | Editorial 
05.02.2021 Covid-19: The E484K mutation and the risks it poses  BMJ | News 
05.02.2021 Vaccines are curbing COVID: Data from Israel show 
drop in infections 
Nature | News  
05.02.2021 What’s the risk of dying from a fast-spreading COVID-
19 variant? 
Nature | News 
05.02.2021 Yemen: Coronavirus in a war zone The Lancet Respiratory 
Medicine | Spotlight 
04.02.2021 How to save the world from long Covid Financial Times | News 
04.02.2021 India budget pledges billions for virus research amid 
COVID pandemic 
Nature | News 
04.02.2021 Could mixing COVID vaccines boost immune 
response? 
Nature | News  
04.02.2021 What went wrong in the global governance of covid-
19? 
BMJ | Editorial 
04.02.2021 Covid-19: social murder, they wrote – elected, 
unaccountable, and unrepentant 
BMJ | Editorial 
05.02.2021 Two new vaccines deliver good and bad news for the 
pandemic 
Science | In depth 
05.02.2021 Danish scientists see tough times ahead as variant 
rises 
Science | In depth 
03.02.2021 Why aren’t covid-19 vaccines being manufactured in 
standard prefilled syringes?  
BMJ | Feature 
02.02.2021 Azithromycin, RECOVERY, and the power of large, 
simple trials  
The Lancet | Comment 
28.01.2021 SARS-CoV-2 vaccines and the growing threat of viral 
variants 
JAMA | Viewpoint 
   
 
Dashboards & Trackers  












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 

















LSTM Stop TB 
Partnership 








  IDA 


































Cell Press Johns Hopkins 
University 



































Institute of Public 
Health 
    






Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv 
and bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
Online learning & events 







for health workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during 
the COVID-19 
pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
is the tole of PFM in 
the “new normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
community health 
workers on the 
COVID-19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 




  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 












Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 




WHO Academy and 
WHO Info mobile 
applications 





Modelling and Policy 









11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 












online brief with Dr 
David Nabarro 














training for the 
coronavirus disease 
outbreak 

































6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 





of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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